CA2827585A1 - Statine et acides gras omega-3 (epa, dha et dpa) utilises dans les maladies cardiovasculaires - Google Patents

Statine et acides gras omega-3 (epa, dha et dpa) utilises dans les maladies cardiovasculaires Download PDF

Info

Publication number: CA2827585A1
Authority: CA; Canada
Prior art keywords: omega; formulation; dha; epa; acid
Prior art date: 2011-02-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2827585A

Other languages

English (en)

Inventor

George Jackowski

Rachelle MACSWEENEY

Nisar Shaikh

Jason Yantha

Valerie SCHINI-KERTH

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pivotal Therapeutics Inc

Original Assignee

Pivotal Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-16

Filing date

2012-02-14

Publication date

2012-08-23

2012-02-14 Application filed by Pivotal Therapeutics Inc filed Critical Pivotal Therapeutics Inc

2012-08-23 Publication of CA2827585A1 publication Critical patent/CA2827585A1/fr

Status Abandoned legal-status Critical Current

Links

235000020660 omega-3 fatty acid Nutrition 0.000 title claims abstract description 102
229940012843 omega-3 fatty acid Drugs 0.000 title claims abstract description 69
239000006014 omega-3 oil Substances 0.000 title claims abstract description 37
229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 24
208000024172 Cardiovascular disease Diseases 0.000 title claims description 55
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 234
239000000203 mixture Substances 0.000 claims abstract description 139
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 135
235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 135
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 135
229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 135
235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 126
229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 117
238000009472 formulation Methods 0.000 claims abstract description 81
YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims abstract description 35
235000021294 Docosapentaenoic acid Nutrition 0.000 claims abstract description 35
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 34
230000009467 reduction Effects 0.000 claims abstract description 33
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 32
238000011282 treatment Methods 0.000 claims abstract description 32
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 29
235000021342 arachidonic acid Nutrition 0.000 claims abstract description 17
229940114079 arachidonic acid Drugs 0.000 claims abstract description 17
101710095342 Apolipoprotein B Proteins 0.000 claims abstract description 11
102100040202 Apolipoprotein B-100 Human genes 0.000 claims abstract description 11
OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims abstract description 10
JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims abstract description 10
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims abstract description 9
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims abstract description 9
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims abstract description 9
235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 8
125000004432 carbon atom Chemical group C* 0.000 claims abstract 7
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 38
239000002775 capsule Substances 0.000 claims description 23
229960000905 indomethacin Drugs 0.000 claims description 19
150000003626 triacylglycerols Chemical class 0.000 claims description 19
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 17
206010020772 Hypertension Diseases 0.000 claims description 15
239000002552 dosage form Substances 0.000 claims description 13
230000000304 vasodilatating effect Effects 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 9
230000002459 sustained effect Effects 0.000 claims description 9
FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims description 8
229960002965 pravastatin Drugs 0.000 claims description 8
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 8
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
206010042434 Sudden death Diseases 0.000 claims description 6
125000004494 ethyl ester group Chemical group 0.000 claims description 6
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims description 5
239000003826 tablet Substances 0.000 claims description 5
230000001225 therapeutic effect Effects 0.000 claims description 5
VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 claims description 4
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 4
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 4
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 4
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 4
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 4
229960005370 atorvastatin Drugs 0.000 claims description 4
229960005110 cerivastatin Drugs 0.000 claims description 4
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 4
229950003040 dalvastatin Drugs 0.000 claims description 4
229960003765 fluvastatin Drugs 0.000 claims description 4
229960004844 lovastatin Drugs 0.000 claims description 4
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 4
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 4
150000003904 phospholipids Chemical class 0.000 claims description 4
229960002797 pitavastatin Drugs 0.000 claims description 4
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 4
229960000672 rosuvastatin Drugs 0.000 claims description 4
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 4
229960002855 simvastatin Drugs 0.000 claims description 4
239000008187 granular material Substances 0.000 claims description 3
239000006187 pill Substances 0.000 claims description 3
239000000843 powder Substances 0.000 claims description 3
239000003381 stabilizer Substances 0.000 claims description 3
239000000725 suspension Substances 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 2
229930003799 tocopherol Natural products 0.000 claims description 2
239000011732 tocopherol Substances 0.000 claims description 2
235000010384 tocopherol Nutrition 0.000 claims description 2
229960001295 tocopherol Drugs 0.000 claims description 2
125000002640 tocopherol group Chemical group 0.000 claims 1
238000000034 method Methods 0.000 abstract description 19
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract description 13
239000003814 drug Substances 0.000 abstract description 11
229940079593 drug Drugs 0.000 abstract description 8
230000002401 inhibitory effect Effects 0.000 abstract description 3
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract description 2
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract description 2
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 56
210000003038 endothelium Anatomy 0.000 description 41
230000001419 dependent effect Effects 0.000 description 38
102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 36
108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 36
210000004369 blood Anatomy 0.000 description 31
239000008280 blood Substances 0.000 description 31
235000014113 dietary fatty acids Nutrition 0.000 description 20
229930195729 fatty acid Natural products 0.000 description 20
239000000194 fatty acid Substances 0.000 description 20
150000004665 fatty acids Chemical class 0.000 description 20
102000007330 LDL Lipoproteins Human genes 0.000 description 16
108010007622 LDL Lipoproteins Proteins 0.000 description 16
230000000694 effects Effects 0.000 description 16
210000004351 coronary vessel Anatomy 0.000 description 15
239000003112 inhibitor Substances 0.000 description 14
239000000047 product Substances 0.000 description 14
210000002889 endothelial cell Anatomy 0.000 description 13
235000021301 omega-3 deficiency Nutrition 0.000 description 13
102000015779 HDL Lipoproteins Human genes 0.000 description 12
108010010234 HDL Lipoproteins Proteins 0.000 description 12
230000001965 increasing effect Effects 0.000 description 12
230000008859 change Effects 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 10
230000026731 phosphorylation Effects 0.000 description 10
238000006366 phosphorylation reaction Methods 0.000 description 10
230000004913 activation Effects 0.000 description 9
235000012000 cholesterol Nutrition 0.000 description 9
150000002632 lipids Chemical class 0.000 description 9
208000032928 Dyslipidaemia Diseases 0.000 description 8
208000017170 Lipid metabolism disease Diseases 0.000 description 8
229930003427 Vitamin E Natural products 0.000 description 8
238000009826 distribution Methods 0.000 description 8
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
230000001196 vasorelaxation Effects 0.000 description 8
235000019165 vitamin E Nutrition 0.000 description 8
239000011709 vitamin E Substances 0.000 description 8
229940046009 vitamin E Drugs 0.000 description 8
210000004204 blood vessel Anatomy 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000006872 improvement Effects 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
230000037361 pathway Effects 0.000 description 7
230000003389 potentiating effect Effects 0.000 description 7
KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
102000000584 Calmodulin Human genes 0.000 description 6
108010041952 Calmodulin Proteins 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
230000008901 benefit Effects 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
235000021323 fish oil Nutrition 0.000 description 6
230000002102 hyperpolarization Effects 0.000 description 6
239000012528 membrane Substances 0.000 description 6
208000010125 myocardial infarction Diseases 0.000 description 6
229940127293 prostanoid Drugs 0.000 description 6
150000003814 prostanoids Chemical class 0.000 description 6
238000012360 testing method Methods 0.000 description 6
101710126338 Apamin Proteins 0.000 description 5
KBFUQFVFYYBHBT-UHFFFAOYSA-N TRAM-34 Chemical compound ClC1=CC=CC=C1C(N1N=CC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 KBFUQFVFYYBHBT-UHFFFAOYSA-N 0.000 description 5
238000000540 analysis of variance Methods 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000036765 blood level Effects 0.000 description 5
239000011575 calcium Substances 0.000 description 5
238000002648 combination therapy Methods 0.000 description 5
208000029078 coronary artery disease Diseases 0.000 description 5
230000002950 deficient Effects 0.000 description 5
235000005911 diet Nutrition 0.000 description 5
YVIIHEKJCKCXOB-STYWVVQQSA-N molport-023-276-178 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(N[C@@H](CSSC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)=O)CC(C)C)[C@@H](C)O)C(N)=O)C1=CNC=N1 YVIIHEKJCKCXOB-STYWVVQQSA-N 0.000 description 5
239000003642 reactive oxygen metabolite Substances 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
241000251468 Actinopterygii Species 0.000 description 4
108091006146 Channels Proteins 0.000 description 4
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 4
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 4
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 4
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 4
102000004257 Potassium Channel Human genes 0.000 description 4
239000000654 additive Substances 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000036996 cardiovascular health Effects 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
230000008602 contraction Effects 0.000 description 4
230000003511 endothelial effect Effects 0.000 description 4
229960001123 epoprostenol Drugs 0.000 description 4
230000036541 health Effects 0.000 description 4
210000002464 muscle smooth vascular Anatomy 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
108020001213 potassium channel Proteins 0.000 description 4
230000002265 prevention Effects 0.000 description 4
230000000770 proinflammatory effect Effects 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
230000002792 vascular Effects 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
102000016938 Catalase Human genes 0.000 description 3
108010053835 Catalase Proteins 0.000 description 3
101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 3
108010037464 Cyclooxygenase 1 Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
208000035150 Hypercholesterolemia Diseases 0.000 description 3
102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
108091007960 PI3Ks Proteins 0.000 description 3
-1 Polyethylene Polymers 0.000 description 3
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
230000002411 adverse Effects 0.000 description 3
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
230000003143 atherosclerotic effect Effects 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
230000000378 dietary effect Effects 0.000 description 3
235000015872 dietary supplement Nutrition 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
235000020774 essential nutrients Nutrition 0.000 description 3
235000019387 fatty acid methyl ester Nutrition 0.000 description 3
208000006575 hypertriglyceridemia Diseases 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
238000002483 medication Methods 0.000 description 3
150000004712 monophosphates Chemical class 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
235000020665 omega-6 fatty acid Nutrition 0.000 description 3
229940033080 omega-6 fatty acid Drugs 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
102000009076 src-Family Kinases Human genes 0.000 description 3
108010087686 src-Family Kinases Proteins 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
230000009469 supplementation Effects 0.000 description 3
230000002227 vasoactive effect Effects 0.000 description 3
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102000003727 Caveolin 1 Human genes 0.000 description 2
108090000026 Caveolin 1 Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000034656 Contusions Diseases 0.000 description 2
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 2
108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
206010016260 Fatty acid deficiency Diseases 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
238000008214 LDL Cholesterol Methods 0.000 description 2
229930184725 Lipoxin Natural products 0.000 description 2
102000003820 Lipoxygenases Human genes 0.000 description 2
108090000128 Lipoxygenases Proteins 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
108091006629 SLC13A2 Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 2
108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 2
206010049418 Sudden Cardiac Death Diseases 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
235000021068 Western diet Nutrition 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
206010003119 arrhythmia Diseases 0.000 description 2
235000004251 balanced diet Nutrition 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000019007 dietary guidelines Nutrition 0.000 description 2
HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
150000002148 esters Chemical group 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
229960004488 linolenic acid Drugs 0.000 description 2
150000002639 lipoxins Chemical class 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
150000004668 long chain fatty acids Chemical class 0.000 description 2
238000007726 management method Methods 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000000116 mitigating effect Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000007505 plaque formation Effects 0.000 description 2
150000008442 polyphenolic compounds Chemical class 0.000 description 2
235000013824 polyphenols Nutrition 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
230000006442 vascular tone Effects 0.000 description 2
230000024883 vasodilation Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
AVKOENOBFIYBSA-WMPRHZDHSA-N (4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O AVKOENOBFIYBSA-WMPRHZDHSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical compound N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
FRDRBZVVFVGENG-UHFFFAOYSA-N 5,10,15,20-tetrakis(1-methyl-2H-pyridin-4-yl)-21,23-dihydroporphyrin Chemical compound CN1CC=C(C=C1)c1c2ccc(n2)c(C2=CCN(C)C=C2)c2ccc([nH]2)c(C2=CCN(C)C=C2)c2ccc(n2)c(C2=CCN(C)C=C2)c2ccc1[nH]2 FRDRBZVVFVGENG-UHFFFAOYSA-N 0.000 description 1
OQOCQFSPEWCSDO-JLNKQSITSA-N 6Z,9Z,12Z,15Z,18Z-Heneicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O OQOCQFSPEWCSDO-JLNKQSITSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
101150104494 CAV1 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
102000009193 Caveolin Human genes 0.000 description 1
108050000084 Caveolin Proteins 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
206010013911 Dysgeusia Diseases 0.000 description 1
206010048554 Endothelial dysfunction Diseases 0.000 description 1
102400000686 Endothelin-1 Human genes 0.000 description 1
101800004490 Endothelin-1 Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
101710113864 Heat shock protein 90 Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
102100035792 Kininogen-1 Human genes 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229910020700 Na3VO4 Inorganic materials 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
241000282887 Suidae Species 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
206010047281 Ventricular arrhythmia Diseases 0.000 description 1
241000219094 Vitaceae Species 0.000 description 1
GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
229960002122 acebutolol Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940066481 amlodipine 10 mg Drugs 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
230000036523 atherogenesis Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
108010051874 catalase-polyethylene glycol Proteins 0.000 description 1
210000004323 caveolae Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000003026 cod liver oil Substances 0.000 description 1
235000012716 cod liver oil Nutrition 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
235000019673 concord grape juice Nutrition 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229940066901 crestor Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
235000021045 dietary change Nutrition 0.000 description 1
235000001434 dietary modification Nutrition 0.000 description 1
235000021004 dietary regimen Nutrition 0.000 description 1
229960001342 dinoprost Drugs 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
230000008694 endothelial dysfunction Effects 0.000 description 1
230000008753 endothelial function Effects 0.000 description 1
239000000066 endothelium dependent relaxing factor Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
239000011536 extraction buffer Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000021021 grapes Nutrition 0.000 description 1
230000036433 growing body Effects 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
OQOCQFSPEWCSDO-UHFFFAOYSA-N heneicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCC(O)=O OQOCQFSPEWCSDO-UHFFFAOYSA-N 0.000 description 1
239000002035 hexane extract Substances 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940082099 irbesartan 300 mg Drugs 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
229940115970 lovaza Drugs 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
230000001483 mobilizing effect Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
230000036651 mood Effects 0.000 description 1
235000021288 n-6 DPA Nutrition 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000007427 paired t-test Methods 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000021085 polyunsaturated fats Nutrition 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
235000017924 poor diet Nutrition 0.000 description 1
238000010149 post-hoc-test Methods 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
150000003109 potassium Chemical class 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
229940076155 protein modulator Drugs 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
235000020095 red wine Nutrition 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000010666 regulation of catalytic activity Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
235000014102 seafood Nutrition 0.000 description 1
230000000276 sedentary effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
208000014221 sudden cardiac arrest Diseases 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000002885 thrombogenetic effect Effects 0.000 description 1
150000003591 thromboxane A2 derivatives Chemical class 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
230000009478 tonic inhibition Effects 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
230000002883 vasorelaxation effect Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2827585A 2011-02-16 2012-02-14 Statine et acides gras omega-3 (epa, dha et dpa) utilises dans les maladies cardiovasculaires Abandoned CA2827585A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161457267P	2011-02-16	2011-02-16
US61/457,267		2011-02-16
PCT/US2012/025026 WO2012112531A1 (fr)	2011-02-16	2012-02-14	Statine et acides gras oméga-3 (epa, dha et dpa) utilisés dans les maladies cardiovasculaires

Publications (1)

Publication Number	Publication Date
CA2827585A1 true CA2827585A1 (fr)	2012-08-23

Family

ID=45755571

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2827585A Abandoned CA2827585A1 (fr)	2011-02-16	2012-02-14	Statine et acides gras omega-3 (epa, dha et dpa) utilises dans les maladies cardiovasculaires

Country Status (4)

Country	Link
EP (1)	EP2675445A1 (fr)
JP (1)	JP2014505732A (fr)
CA (1)	CA2827585A1 (fr)
WO (1)	WO2012112531A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2118074T3 (en)	2007-02-01	2014-03-10	Resverlogix Corp	Compounds for the prevention and treatment of cardiovascular diseases
KR101709492B1 (ko)	2009-03-18	2017-02-23	리스버로직스 코퍼레이션	신규한 소염제
US9757368B2 (en)	2009-04-22	2017-09-12	Resverlogix Corp.	Anti-inflammatory agents
CN107050457A (zh)	2012-01-06	2017-08-18	翁特拉制药公司	游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
EP2846779A4 (fr)	2012-05-07	2015-12-16	Omthera Pharmaceuticals Inc	Compositions de statines et d'acides gras oméga-3
WO2013192109A1 (fr)	2012-06-17	2013-12-27	Matinas Biopharma, Inc.	Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation
EP2928462A4 (fr) *	2012-12-06	2016-06-01	Matinas Biopharma Inc	Procédés d'administration de compositions comprenant de l'acide docosapentaénoïque
US20160346291A1 (en) *	2013-08-21	2016-12-01	Resverlogix Corp	Compositions and therapeutic methods for accelerated plaque regression
JP2016528275A (ja) *	2013-08-21	2016-09-15	レスバーロジックスコーポレイション	プラーク退縮を促進するための組成物及び治療法
US10111885B2 (en)	2015-03-13	2018-10-30	Resverlogix Corp.	Compositions and therapeutic methods for the treatment of complement-associated diseases
EP3586640A1 (fr)	2018-06-21	2020-01-01	Nuseed Pty Ltd	Compositions d'acides gras polyinsaturés enrichies en dha
EP3586641A1 (fr)	2018-06-21	2020-01-01	Nuseed Pty Ltd	Compositions d'acides gras polyinsaturés enrichies en dha
EP3586642A1 (fr)	2018-06-21	2020-01-01	Nuseed Pty Ltd	Compositions d'acides gras polyinsaturés enrichies en ala
EP3586643A1 (fr)	2018-06-21	2020-01-01	Nuseed Pty Ltd	Compositions d'acides gras polyinsaturés enrichies en dha

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2862873A1 (fr) *	2003-12-01	2005-06-03	Pf Medicament	Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
BRPI0518398A2 (pt) *	2004-12-06	2008-11-18	Reliant Pharmaceuticals Inc	Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos
EP2364701A1 (fr) *	2005-12-20	2011-09-14	Cenestra, Llc	Formulation comportant de l'acide gras oméga-3
PL1800675T4 (pl) *	2005-12-23	2012-02-29	Nutricia Nv	Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia
EP4137128A1 (fr) *	2008-09-02	2023-02-22	Amarin Pharmaceuticals Ireland Limited	Composition pharmaceutique contenant de l'acide eicosapentaénoïque et leurs procédés d'utilisation
US9532963B2 (en) *	2009-03-09	2017-01-03	Pronova Biopharma Norge As	Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
US20100239660A1 (en) *	2009-03-19	2010-09-23	Doughman Scott D	Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions

2012
- 2012-02-14 CA CA2827585A patent/CA2827585A1/fr not_active Abandoned
- 2012-02-14 WO PCT/US2012/025026 patent/WO2012112531A1/fr not_active Ceased
- 2012-02-14 EP EP12705591.1A patent/EP2675445A1/fr not_active Withdrawn
- 2012-02-14 JP JP2013554544A patent/JP2014505732A/ja active Pending

Also Published As

Publication number	Publication date
WO2012112531A1 (fr)	2012-08-23
JP2014505732A (ja)	2014-03-06
EP2675445A1 (fr)	2013-12-25

Legal Events

Date	Code	Title	Description
2017-03-29	FZDE	Discontinued	Effective date: 20170215

Publication	Publication Date	Title
WO2012112531A1 (fr)	2012-08-23	Statine et acides gras oméga-3 (epa, dha et dpa) utilisés dans les maladies cardiovasculaires
US20150246012A1 (en)	2015-09-03	Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagnostic assay for the dietary management of cardiovascular patients with cardiovascular disease (cvd) who are deficient in blood epa and dha levels
WO2014179341A1 (fr)	2014-11-06	Traitement par des compositions d'acide gras oméga-3
US20150119414A1 (en)	2015-04-30	Statin and omega 3 fatty acids for reduction of apolipoprotein-b levels
WO2012112517A1 (fr)	2012-08-23	Test diagnostique des taux d'acides gras oméga-3 pour la prise en charge alimentaire des patients atteints d'une maladie cardiovasculaire
AU2013354969A1 (en)	2015-06-11	Omega-3 pentaenoic acid compositions and methods of use
US20150224075A1 (en)	2015-08-13	Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
CA2827579A1 (fr)	2012-08-23	Preparations a base d'omega-3 comprenant epa, dha et dpa pour le traitement des facteurs de risque dans la maladie cardiovasculaire
US8715648B2 (en)	2014-05-06	Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
CA2827555A1 (fr)	2012-08-23	Inhibiteur de l'absorption du cholesterol (azetidinone) et acides gras omega 3 (epa, dha, dpa) pour la reduction du cholesterol et pour la reduction des evenements cardiovasculaires
US20060009486A1 (en)	2006-01-12	Composition and method for treatment and prevention of coronary artery disease
US9248138B2 (en)	2016-02-02	Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acids
WO2012112520A1 (fr)	2012-08-23	Préparations comprenant des acides gras oméga-3 et un agent anti-obésité pour la réduction du poids corporel chez les patients atteints d'une maladie cardiovasculaire et chez les diabétiques
US8952000B2 (en)	2015-02-10	Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
WO2015106177A1 (fr)	2015-07-16	Procédé et composition de stabilisation de plaques vulnerables à l'aide d'une combinaison composée d'une statine et d'acides gras omega 3
US20150272920A1 (en)	2015-10-01	Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics